title: [Intraoperative radiofrequency ablation and 125I therapy for preventing local recurrence in hepatocellular carcinoma after hepatectorny].
abstract: OBJECTIVE
  To evaluate the efficacy of intraoperative radiofrequency ablation and 125I therapy for preventing local recurrence in hepatocellular carcinoma (HCC) after hepatectomy.
  
  
  METHODS
  Seventy-eight HCC patients with a tumor close to the first or the second hepatic portal underwent hepatectomy with a resection margin less than 1 cm from 1999 to 2001. All patients were randomly divided into control group and combined treatment group according to their check-in date (odd or even). In the control group, 38 patients were treated with hepatectomy alone, whereas in the combined group, 40 patients were treated with hepatectomy plus radiofrequency ablation and 125I implantation on surgical margin. All patients were followed up regularly.
  
  
  RESULTS
  the 1-, 3- and 5-year recurrent rate was 7.5%, 30.0% and 45.0% in the combined treatment group versus 18.4%, 60.5% and 86.8% in the control group, respectively, with a significant difference in the 3-year (chi2 = 7.340, P < 0.01) and 5-year recurrent rates (chi2 = 15.740, P < 0.01). The 1-, 3- and 5-year survival rate was 92.5%, 67.5% and 30.0% in the combined group versus 81.5%, 39.4% and 18.4%, respectively.
  
  
  CONCLUSIONS
  Intraoperative radiofrequency ablation and 125I therapy on the resection margin is effective to prevent local recurrence in HCC patients after hepatectomy, and to prolong their postoperative tumor free survival.
authors.affiliation: Department of General Surgery, Second People's Hospital of Guangdong Province, Guangzhou 510317, China. chky3213300@126.com
authors.forename: Kai-yun
authors.initials: KY
authors.lastname: Chen
authors.forename: Guo-an
authors.initials: GA
authors.lastname: Xiang
authors.forename: Han-ning
authors.initials: HN
authors.lastname: Wang
authors.forename: Fang-lian
authors.initials: FL
authors.lastname: Xiao
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001145:Arrhythmias, Cardiac / Q000209:etiology; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000532:radiotherapy / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D007432:Intraoperative Period; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000097:blood / Q000532:radiotherapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D015996:Survival Rate
chemical_list: D007457:Iodine Radioisotopes; D000410:Alanine Transaminase